Is Ozempic a peptide? How tirzepatide and semaglutide are built

The short answer: yes, Ozempic is a peptide medicine, and so is tirzepatide

Ozempic is a peptide medicine, and so is tirzepatide, the medicine in Zepbound and Mounjaro. Both prescribing labels use the word themselves. The Zepbound label says tirzepatide "is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid, and amide hydrolysis." The Ozempic label says the medicine contains semaglutide, a human GLP-1 receptor agonist, and that "the peptide backbone is produced by yeast fermentation."

So when people ask whether these are "peptides" the way research peptides are peptides, the honest answer is that they share a chemical category and nothing else. Tirzepatide and semaglutide are chains of amino acids that were designed, modified and run through the drug approval process. Ozempic is indicated, per its label, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.

What makes a molecule a peptide, and where the FDA draws the line at 40 amino acids

Amino acids link together into chains. Short chains are called peptides. Long ones are called proteins. The dividing line is not poetic, it is written into federal regulation. In its 2020 final rule Definition of the Term "Biological Product", the FDA states that "the term protein means any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size." The same rule notes that the term "peptide" generally refers to smaller, simpler chains of amino acids, while "protein" is used to refer to longer, more complex chains.

Now the sequence lengths. The federal substance registration record for tirzepatide lists a sequence length of 39. The record for semaglutide lists a sequence length of 31. Both sit under the 40 amino acid line in the final rule, which is the plain reason both are discussed as peptides rather than proteins.

That is a chemistry fact about chain length. It says nothing about how any product is approved, sold or substituted.

Tirzepatide and semaglutide side by side: how each GLP-1 peptide is built

The short version: tirzepatide was built off the GIP sequence and acts at two receptors, while semaglutide was built close to human GLP-1 and acts at one. Both carry a fatty acid chain that binds albumin, the blood protein, which the Zepbound label says "enables albumin binding and prolongs the half-life." If you want the clinical comparison rather than the chemistry, read tirzepatide vs semaglutide.

Why these peptides last a week, and where tablets fit

Unmodified GLP-1 in the body breaks down fast. The modifications described on these labels are what change that. The Ozempic label says semaglutide is modified in position 8 "to provide stabilization against degradation by the enzyme dipeptidyl-peptidase 4 (DPP-4)," and that its main protraction mechanism is albumin binding.

In label words: tirzepatide is injected subcutaneously once weekly. For semaglutide, the Ozempic label states that "with an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for about 5 weeks after the last dose."

Tablets exist on the semaglutide side. The oral semaglutide label instructs patients to "take RYBELSUS or OZEMPIC tablets orally once daily on an empty stomach in the morning with water (up to 4 ounces of water)," and NovoCare lists Wegovy injection and Wegovy tablets as prescription medicines. There is no tirzepatide tablet: as of 2026-09-28, every tirzepatide label listed on DailyMed is an injection, solution.

Your provider decides which form and which schedule fit you. Nothing here is dosing advice.

Is Ozempic made from animals or venom?

No. Per the Ozempic label, the semaglutide peptide backbone is produced by yeast fermentation, then chemically modified at position 26 and position 8 as described above. There is no animal tissue and no venom in that description.

The lizard story people are thinking of belongs to a different GLP-1 medicine. The Byetta label says "BYETTA (exenatide) is a synthetic peptide, GLP-1 receptor agonist, that was originally identified in the lizard Heloderma suspectum," and that "exenatide is a 39-amino acid peptide amide." That is exenatide, not tirzepatide and not semaglutide.

Why GLP-1 peptides can upset your stomach

Here are two sets of label facts, placed side by side, without drawing a causal line between them.

• Gastric emptying: the Zepbound label states that "ZEPBOUND delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications." The Ozempic label states that "semaglutide causes a delay of early postprandial gastric emptying, thereby reducing the rate at which glucose appears in the circulation postprandially."
• Adverse reactions: the Zepbound label lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss and gastroesophageal reflux disease among the most common adverse reactions reported in at least 5% of patients. The Ozempic label lists nausea, vomiting, diarrhea, abdominal pain and constipation among the most common adverse reactions reported in at least 5% of patients.

Talk to your prescriber about side effects you are having, especially if they are severe or persistent.

FDA-approved brand, compounded prescription and research-use-only vials: three different things

These get blurred constantly online. They are not the same category.

1. FDA-approved brand products. Zepbound, Mounjaro, Ozempic and Wegovy are approved finished products with FDA-reviewed labels, sold under those brand names.
2. Compounded medications. The FDA describes compounding as a practice in which a licensed pharmacist, a licensed physician, or a person under the supervision of a licensed pharmacist "combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient," and states that compounded drugs are not FDA approved, "which means the agency does not review their safety, effectiveness or quality before they are marketed." Compounded medications are not FDA approved finished products. A licensed provider determines eligibility.
3. Products falsely labeled for research purposes. The FDA has warned companies that illegally sold unapproved drugs containing tirzepatide, semaglutide and other GLP-1 molecules "falsely labeled 'for research purposes' or 'not for human consumption,'" sold directly to consumers with dosing instructions. The agency "urges consumers not to purchase these products which are of unknown quality and may be harmful to their health." We cover that notice in what the FDA statement on unapproved GLP-1 drugs means for you.

Belle does not sell Ozempic or any brand GLP-1. Belle offers compounded tirzepatide and compounded semaglutide by prescription through a licensed clinician, filled by a state-licensed pharmacy. Compounded medications are custom-prepared by licensed compounding pharmacies and are not evaluated by the U.S. Food and Drug Administration (FDA) for safety or effectiveness. See Belle's important safety information. A compounded prescription is a separately prepared medication, not a brand product, and the facts on a brand label describe that brand product only. For more on the distinction, read compounded semaglutide vs Wegovy and Ozempic.

What GLP-1 medicines cost and how to get a prescription

Brand self-pay prices are published by the manufacturers and change. As of 2026-09-16, LillyDirect listed Zepbound single-dose vial self-pay prices "starting at $299/month" for the starting dosage vial, "starting at $399/month" for the next vial strength, and "starting at $449/month" for the following strength when you refill within 45 days, with terms and conditions and a needle and syringe purchase required.

As of 2026-09-16, NovoCare stated that patients new to the Wegovy Savings offer or NovoCare Pharmacy "pay $199 for each month" of the two lowest strengths, an offer for 2 monthly fills through December 31, 2026, "then $349 per month" for the listed Wegovy strengths and "$399 per month" for Wegovy HD, with eligibility and restrictions applying.

Belle's own pricing for compounded treatment is shown live below, so you are always reading the current number rather than a figure typed into an article.

The FDA's guidance on getting GLP-1 medicine safely is short: "Patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy." If you are starting from scratch, how peptide telehealth works walks through the visit, the review and the delivery step by step.

Other peptides are covered in their own guides, and peptides other than approved drugs are investigational: sermorelin, BPC-157, the copper peptide guide and one more peptide guide.